Increased One-Year Recurrent Ischemic Stroke after First-Ever Ischemic Stroke in Males with Benign Prostatic Hyperplasia

Int J Environ Res Public Health. 2020 Jul 25;17(15):5360. doi: 10.3390/ijerph17155360.

Abstract

(1) Background: Patients with benign prostatic hyperplasia (BPH) were questioned about quality of life and sleep. Most BPH patients were treated with alpha-1 adrenergic receptor antagonists, which could improve cerebral blood flow for 1-2 months. Patients with ischemic stroke (IS) could experience cerebral autoregulation impairment for six months. The relationship between BPH and recurrent IS remains unclear. The aim of this study was to determine the risk of one-year recurrent IS conferred by BPH. (2) Methods: We used data from the Taiwanese National Health Insurance Database to identify newly diagnosed IS cases entered from 1 January 2008 to 31 December 2008. Patients were followed until the recurrent IS event or 365 days after the first hospitalization. The risk factors associated with one-year recurrent IS were assessed using Cox proportional hazards regression. (3) Results: Patients with BPH had a higher risk of recurrent IS (12.11% versus 8.15%) (adjusted hazard ratio (HR): 1.352; 95% confidence interval (CI): 1.028-1.78, p = 0.031). Other risk factors included hyperlipidemia (adjusted HR: 1.338; 95% CI: 1.022-1.751, p = 0.034), coronary artery disease (adjusted HR: 1.487; 95% CI: 1.128-1.961, p = 0.005), chronic obstructive pulmonary disease (adjusted HR: 1.499; 95% CI: 1.075-2.091, p = 0.017), and chronic kidney disease (adjusted HR: 1.523; 95% CI: 1.033-2.244, p = 0.033). (4) Conclusion: Patients with BPH who had these risk factors had an increased risk of one-year recurrent IS. The modification of risk factors may prevent recurrent IS.

Keywords: benign prostatic hyperplasia; cerebral autoregulation dysfunction; one-year recurrent ischemic stroke.

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists / therapeutic use
  • Adult
  • Brain Ischemia / epidemiology*
  • Humans
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Prostatic Hyperplasia / complications*
  • Prostatic Hyperplasia / drug therapy
  • Prostatic Hyperplasia / epidemiology
  • Quality of Life / psychology*
  • Receptors, Adrenergic, alpha-1
  • Risk Factors
  • Stroke / epidemiology*
  • Stroke / etiology
  • Stroke / psychology

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Receptors, Adrenergic, alpha-1